Horga, A. Et Al. 2023. Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY). Future Virology , vol.18, no.13 , 839-853.

Horga, A., Saenz, R., YILMAZ, G., Simón-Campos, A., Pietropaolo, K., Stubbings, W. J., ... Collinson, N.(2023). Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY). Future Virology , vol.18, no.13, 839-853.

Horga, Arantxa Et Al. "Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)," Future Virology , vol.18, no.13, 839-853, 2023

Horga, Arantxa Et Al. "Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)." Future Virology , vol.18, no.13, pp.839-853, 2023

Horga, A. Et Al. (2023) . "Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)." Future Virology , vol.18, no.13, pp.839-853.

@article{article, author={Arantxa Horga Et Al. }, title={Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)}, journal={Future Virology}, year=2023, pages={839-853} }